Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

Inclusion Criteria:

• Signed consent obtained before any study-related activities (study-related activitiesare any procedure related to recording of data according to the protocol).
• The decision to initiate treatment with commercially available Esperoct® has been madeby the patient/Legally Acceptable Representative (LAR) and the treating physicianbefore and independently from the decision to include the patient in this study.
• Diagnosis of haemophilia A in males or females, no age limitation.
• New patients who have not previously been exposed to Esperoct®.

Exclusion Criteria:

• Previous participation in this study. Participation is defined as having giveninformed consent in this study.
• Known or suspected hypersensitivity to study product or related products.
• Mental incapacity, unwillingness or language barriers precluding adequateunderstanding or cooperation.